CETP and obstructive sleep apnea syndrome: Furthermore, emerging evidence suggests that combination pharmacotherapy and agents targeting lipid metabolism, such as cholesteryl ester transfer protein (CETP) inhibitors, may also play a role in reducing OSA risk, highlighting the potential for multi-modal drug strategies in the future (159).